Introduction:
The Novo Nordisk Foundation is embarking on a groundbreaking journey, dedicating its resources to forge a state-of-the-art facility that will serve as the ultimate crucible for advancing cell therapies into their final forms, poised for human testing.
Features:
The facility will cater to a diverse range of clients, encompassing both public and private organizations from academia, biotechnology, and the pharmaceutical sector, at both national and international levels.
The facility will provide support for various types of cell therapies, including those derived from embryonic stem cells, induced pluripotent stem cells, and adult stem cells.
A comprehensive suite of services will be available, spanning from process development to GMP (Good Manufacturing Practice) manufacturing, product release, and regulatory guidance
The facility's design will incorporate flexibility to accommodate the rapidly evolving demands within the field of cell therapy.
The Novo Nordisk Foundation Cellerator stands as an innovative undertaking, being the first large-scale production site to bring together a wide array of expertise and services under a single roof.
The selection of DTU as the site for the Cellerator is influenced, in part, by the university's substantial proficiency in cell manufacturing and its pre-existing infrastructure.
Commencement Date: Operations are expected to begin in 2027.
Specifications:
Name: Novo Nordisk Foundation
Type: Expansion
Year: 2027
